  Apoptosis is a complex pathway regulated by the concerted action of multiple
pro- and anti-apoptotic molecules. The intrinsic (mitochondrial) pathway of
apoptosis is governed up-stream of mitochondria, by the family of Bcl-2
proteins, and down-stream of mitochondria, by low-probability events, such as
apoptosome formation, and by feedback circuits involving caspases and inhibitor
of apoptosis proteins (IAPs), such as XIAP. All these regulatory mechanisms
ensure that cells only commit to death once a threshold of damage has been
reached and the anti-apoptotic reserve of the cell is overcome. As cancer cells
are invariably exposed to strong intracellular and extracellular stress
stimuli, they are particularly reliant on the expression of anti-apoptotic
proteins. Hence, many cancer cells undergo apoptosis when exposed to agents
that inhibit anti-apoptotic Bcl-2 molecules, such as BH3 mimetics, while normal
cells remain relatively insensitive to single agent treatments with the same
class of molecules. Targeting different proteins within the apoptotic network
with combinatorial treatment approaches often achieves even greater
specificity. This led us to investigate the sensitivity of leukemia and
lymphoma cells to a pro-apoptotic action of a BH3 mimetic combined with a small
molecule inhibitor of XIAP. Using computational probabilistic model of
apoptotic pathway, verified by experimental results from human leukemia and
lymphoma cell lines, we show that inhibition of XIAP has a non-linear effect on
sensitization towards apoptosis induced by the BH3 mimetic HA14-1. This study
justifies further ex vivo and animal studies on the potential of the treatment
of leukemia and lymphoma with a combination of BH3 mimetics and XIAP
inhibitors.
